title: [Etiologic treatment of sicca syndrome. What can the rheumatologist offer?].
abstract: No effective treatment has been documented for the glandular primary Sjögren syndrome (PSS) despite the development of oral and biologic agents that have significant activity against other autoimmune disorders. Some disease-modifying agents have been empirically evaluated for the treatment of PSS. Targeting B cells also seems very promising in SSP because of the B-cell hyperactivity recognized in this desease. This article reviews existing data on the use of disease-modifying therapy for glandular of SSP. To date, published studies and trials of oral DMARDs for the treatment of SSP have shown disappointing results. B-cell modulation is clearly a promising therapy for PSS. Many challenges in trial design and execution are evident from the studies reviewed.
authors.affiliation: Servicio de Reumatología, Hospital Puerta de Hierro Majadahonda, Madrid, España.
authors.forename: Monica
authors.initials: M
authors.lastname: Fernández Castro
authors.forename: Lucía
authors.initials: L
authors.lastname: Silva
authors.forename: Teresa
authors.initials: T
authors.lastname: Otón
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Andreu